HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $100

Benzinga Newsdesk www.benzinga.com Neutral 70.8%

Neg 0% Neu 70.8% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $115 to $100.